Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline

Corvus Pharmaceuticals Inc. ((CRVS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Corvus Pharmaceuticals’ latest earnings call struck an optimistic tone as management highlighted strong early efficacy for its lead drug soquelitinib, durable responses, and a clean safety profile across more than 150 patients. These positives, paired with a major capital raise extending cash runway into 2028, helped offset concerns about higher spending, ongoing losses, and long timelines to pivotal data.

Robust Atopic Dermatitis Signal in Cohort 4

Cohort 4 in the atopic dermatitis Phase I study delivered standout results, with a 72% mean reduction in EASI scores versus 40% on placebo and a statistically significant p‑value of 0.035. Seventy‑five percent of treated patients reached EASI‑75, compared with roughly 20% on placebo, underscoring a potentially meaningful efficacy edge.

Durable Responses Suggest Intermittent Dosing Potential

Management emphasized that clinical responses in cohorts 3 and 4 were maintained for up to 90 days after stopping therapy, with more than 90% of patients not relapsing in follow‑up. This durability hints at the possibility of intermittent dosing regimens, which could be attractive for both patients and payers if confirmed in larger trials.

Clean Safety Profile and Limited Viral Risk

Across more than 150 patients and over 14,000 patient‑days of exposure, soquelitinib showed no new safety signals, including no hepatic abnormalities and infection rates similar to placebo. Importantly for an ITK inhibitor, there was no evidence of EBV reactivation, even among patients treated for more than two years, supporting the drug’s long‑term safety case.

Biomarkers Support Immune Rebalancing Mechanism

Biomarker data showed reductions in IL‑4, IL‑5, IL‑17 and a modest decline in TARC, along with decreased Th2 cells and increased regulatory T cells. These shifts are consistent with ITK‑mediated immune rebalancing and provide a mechanistic rationale for expanding soquelitinib into multiple inflammatory diseases beyond atopic dermatitis.

Pipeline Expansion Across Multiple Indications

Corvus is moving aggressively on development, launching a 200‑patient randomized Phase II atopic dermatitis trial with multiple dose arms and a 12‑week treatment plus 90‑day follow‑up, targeting data in mid‑2027. The company is also advancing a Phase III trial in PTCL, and plans Phase II studies in hidradenitis suppurativa and asthma, while its partner pursues an additional AD program in China.

PTCL Survival Data Compare Well to Historical Chemotherapy

In PTCL, Phase I/Ib data for the 200 mg BID dose showed a median progression‑free survival of 6.2 months and median overall survival of 28 months. These results compare favorably with historical chemotherapy benchmarks of under 3.5 months PFS and less than one year OS, positioning soquelitinib as a potential new standard if Phase III results confirm the benefit.

Balance Sheet Strengthened by Upsized Financing

Financially, Corvus ended 2025 with $56.8 million in cash and securities, slightly above the prior year, and then closed an upsized offering that added $189 million in net proceeds. Pro forma cash of roughly $246 million extends the company’s runway into the second quarter of 2028, covering several major trial milestones and reducing near‑term financing pressure.

R&D Spending Surges With Advancing Programs

The flip side of the pipeline’s momentum is sharply higher research and development spending, with Q4 R&D rising to $9.9 million from $6.0 million a year earlier and full‑year R&D surging 73% to $33.7 million. Management attributed the increase to expanding clinical trial activity and manufacturing for soquelitinib, as well as growing headcount to manage the broader portfolio.

Persistent Net Losses and Higher Stock Compensation

Corvus remains firmly in investment mode, posting a Q4 2025 net loss of $12.3 million, slightly deeper than the prior year and including a non‑cash equity loss. Stock‑based compensation doubled to $1.6 million in the quarter, reflecting greater reliance on equity incentives as the company scales its operations and talent base.

Early‑Stage Data Need Confirmation in Larger Trials

Executives stressed that key efficacy signals, including the standout atopic dermatitis results, come from small Phase I cohorts such as the 12 patients in cohort 4. While encouraging, these findings will require confirmation in larger randomized Phase II and Phase III trials before investors can place high confidence on the magnitude and durability of benefit.

Long Timelines and Visibility Challenges

Definitive data are still years away, with primary Phase II atopic dermatitis results not expected until mid‑2027 and full PTCL Phase III readout targeted for late 2027. The company also acknowledged a visibility setback when a high‑profile dermatology conference did not select its late‑breaker abstract, delaying exposure to a key specialist audience despite securing another scientific presentation.

Execution and Capital Allocation Risks Remain

Management highlighted that the PTCL Phase III trial includes a futility analysis, and despite promising early data there is always a risk of disappointing outcomes or regulatory hurdles. With multiple mid‑ and late‑stage trials planned across indications, the finite cash runway to 2028 underscores the importance of disciplined execution and the potential need for future capital depending on results.

Guidance Highlights: Runway to 2028, Key Readouts Ahead

On guidance, Corvus reiterated its expectation that current pro forma cash of about $246 million will fund operations into the second quarter of 2028, encompassing key readouts across the AD, PTCL, hidradenitis suppurativa, asthma and China AD programs. The company framed upcoming milestones, including this year’s interim PTCL analysis and initial China AD data, as crucial de‑risking events ahead of the larger 2027 registrational‑type readouts.

Corvus Pharmaceuticals’ earnings call painted a picture of a high‑risk, high‑reward clinical story, anchored by compelling early data and a fortified balance sheet. For investors, the stock now hinges on the company’s ability to translate small‑cohort successes into large‑scale trial wins over the next several years while managing rising costs and execution complexity.